Cargando…
Oral mycosis fungoides with CD30(+) large cell transformation successfully treated with brentuximab vedotin
Autores principales: | Goggins, Clare A., Gocke, M. Timothy, Jang, Sekwon, DeSimone, Jennifer A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357896/ https://www.ncbi.nlm.nih.gov/pubmed/30733988 http://dx.doi.org/10.1016/j.jdcr.2018.11.013 |
Ejemplares similares
-
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
por: Kim, Youn H., et al.
Publicado: (2021) -
Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013) -
Brentuximab extravasation injury in a patient with mycosis fungoides with large cell transformation
por: Kim, Eileen, et al.
Publicado: (2022) -
Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018) -
Complete response of penile mycosis fungoides with systemic brentuximab therapy
por: Schaufler, Christian, et al.
Publicado: (2020)